Vitamin D3 levels and vitamin D receptor expression may play a significant role in the pathogenesis of thyroid eye disease.

An IGF-1R inhibitor, can have a significant proptosis response and favorable safety profile for active thyroid eye disease.

New research from Spherix Global Insights finds that while Amgen's Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye disease (TED), physicians emphasize ongoing unmet ...

Viridian Therapeutics reported third-quarter 2025 results, revealing revenue of US$70.57 million compared to just US$86,000 a year earlier, and significantly reduced net loss, as well as the ...

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 trials for VRDN-003 in TED are underway, with a BLA submission planned by ...

Thyroid eye disease is a condition that impacts the muscles and tissues around the eyes, causing discomfort and vision difficulties for those affected. Healthcare experts are now employing effective ...

A team led by UCL scientists has identified a key protein that triggers diabetic retinopathy—a condition caused by high blood sugar damaging the retina's blood vessels and a leading cause of sight ...

Please provide your email address to receive an email when new articles are posted on . Teprotumumab-trbw has changed the landscape of thyroid eye disease management. Novel thyroid eye disease drugs ...

During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the blockbuster eye disease med Vabysmo (faricimab). Now, as the co-founder and CEO of ...

With top-line phase 3 results in sight, Rezolute has stepped up preparations for a planned rare disease launch by appointing Sunil Karnawat as its chief commercial officer. Rezolute recently completed ...

(RTTNews) - Viridian Therapeutics, Inc. (VRDN), a biopharmaceutical company, on Wednesday announced that it has entered an exclusive collaboration and licensing deal with Kissei Pharmaceutical to ...